Brilinta Tablet
Product Images NDC 71610-815

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Brilinta (NDC 71610-815). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (71610 815 41)

Label (71610 815 41)
Label for BRILINTA (Ticagrelor) 90 mg oral tablets, showing packaging for 5400 tablets. Includes storage information specifying 20-25 degrees Celsius and USP Controlled Room Temperature guidance. The label lists the manufacturer as AstraZeneca in Sweden and the packager as Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The NDC is 71610-815-41.*
FDA Label Image

Aphena (Aphena)

Aphena (Aphena)
FDA Label Image

Figure_1 (Figure 1)

Figure_1 (Figure 1)
A cumulative percentage graph comparing Ticagrelor 90 mg and Clopidogrel over 360 days from the first study drug dose. The plot shows two lines depicting cumulative event percentages, with a legend indicating the number of patients and event rates for each drug. The x-axis represents days, and the y-axis shows cumulative percentage.*
FDA Label Image

Fiigure_2 (Figure 2)

Fiigure_2 (Figure 2)
A bar chart showing the percentage of patients who had an event following CABG over days 1 through 8 and more. The chart compares two groups labeled T and C, with data presented as percentages and counts below each day on the x-axis. The y-axis represents the percentage of patients, ranging from 0 to 100%.*
FDA Label Image

Chemical Structure (Chemical Structure)

Chemical Structure (Chemical Structure)
Chemical structure of Ticagrelor, the active ingredient in BRILINTA 90 mg oral tablets by Aphena Pharma Solutions. The diagram shows the molecular arrangement of atoms and bonds characteristic of Ticagrelor.*
FDA Label Image

Figure_8 (Figure 08)

Figure_8 (Figure 08)
A comparative pharmacokinetic chart illustrating the mean effect and 90% confidence intervals of various interacting drugs on Ticagrelor versus AR-C124910XX. The chart shows changes relative to reference values for Cmax (maximum concentration) and AUC (area under the curve). The graph includes drugs such as Ketoconazole, Diltiazem, Rifampin, Aspirin, Desmopressin, Heparin, Enoxaparin, Cyclosporine, Morphine, and Fentanyl, alongside corresponding dosing and recommendations regarding dose adjustments or concomitant use.*
FDA Label Image

Figure_10 (Figure 10)

Figure_10 (Figure 10)
A line graph comparing cumulative percentage events over 360 days between Ticagrelor 90 mg and Clopidogrel. The y-axis shows cumulative percentage, and the x-axis shows days from randomization. The graph includes a legend with patient numbers and statistical data such as hazard ratio and p-value. At risk patient counts are listed below the x-axis for both treatments over time.*
FDA Label Image

Figure_11 (Figure 11)

Figure_11 (Figure 11)
A forest plot comparing the treatment effects of Ticagrelor and Clopidogrel on various characteristics such as geographic region, aspirin dose, treatment approach, diabetes history, age group, sex, and race. The x-axis shows hazard ratios (HR) with 95% confidence intervals, indicating whether Ticagrelor or Clopidogrel is favored.*
FDA Label Image

Figure_12 (Figure 12)

Figure_12 (Figure 12)
A forest plot chart comparing the hazard ratios (HR) and 95% confidence intervals (CI) for Ticagrelor versus Clopidogrel across different aspirin (ASA) dose groups and regions (US and Non-US). The chart displays numeric values for Ticagrelor and Clopidogrel event counts, with a visual representation of whether Ticagrelor or Clopidogrel is favored based on HR values along the x-axis.*
FDA Label Image

Figure_13 (Figure 13)

Figure_13 (Figure 13)
A Kaplan-Meier curve showing cumulative percentage of events over days from randomization for three groups: Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo. The graph includes patient counts at risk over time, event percentages, hazard ratios with confidence intervals, and p-values for comparisons between groups.*
FDA Label Image

Figure_14 (Figure 14)

Figure_14 (Figure 14)
A forest plot comparing the overall treatment effect and various subgroups for Ticagrelor versus placebo. The chart shows hazard ratios (HR) with 95% confidence intervals across categories such as age, sex, race, weight group, BMI, geographic region, prior medical history, type of qualifying myocardial infarction, diabetes status, coronary artery disease, kidney function, prior PCI, stent type, smoking status, and time since previous ADP receptor blocker treatment.*
FDA Label Image

Figure_15 (Figure 15)

Figure_15 (Figure 15)
A line graph depicting cumulative percentage over months from randomization comparing Ticagrelor and placebo. The solid line represents Ticagrelor, and the dashed line represents placebo, showing cumulative percentage increase over approximately 54 months. The chart includes numbers of patients at risk over time for both groups.*
FDA Label Image

Figure_16 (Figure 16)

Figure_16 (Figure 16)
A forest plot displaying hazard ratios (HR) with 95% confidence intervals (CI) for various patient subgroups comparing Ticagrelor versus placebo. Subgroups include age, sex, race, BMI, geographic region, aspirin dose, HbA1c, eGFR, insulin use, history of angina, coronary artery disease, PCI, CABG, smoking status, and diabetes duration. The plot visually compares outcomes to show where Ticagrelor or placebo is favored.*
FDA Label Image

Figure_17 (Figure 17)

Figure_17 (Figure 17)
A Kaplan-Meier curve chart comparing cumulative event percentages over days from randomization between Ticagrelor 90 mg twice daily and placebo groups. The chart shows cumulative percentages on the y-axis and days from randomization on the x-axis, with data tables indicating numbers at risk for both groups at various time points.*
FDA Label Image

Figure_18 (Figure 18)

Figure_18 (Figure 18)
A forest plot illustrating hazard ratios (HR) with 95% confidence intervals comparing the efficacy outcomes of Ticagrelor versus placebo across various patient subgroups. The subgroups include age, sex, race, weight, BMI, geographic region, diagnosis, time to treatment, diabetes, hypertension, prior medical history, statin use, and smoking status. The plot shows HR points mostly favoring Ticagrelor (left side) across most characteristics.*
FDA Label Image

Figure_3 (Figure 3)

Figure_3 (Figure 3)
A cumulative percentage line graph comparing Ticagrelor and placebo over approximately 54 months from randomization, showing cumulative percentage on the y-axis and months on the x-axis. The graph includes lines for Ticagrelor (solid) and placebo (dashed) with corresponding event counts and sample sizes indicated in a legend. The number of subjects at risk is tabulated below the x-axis.*
FDA Label Image

Figure_4 (Figure 4)

Figure_4 (Figure 4)
A Kaplan-Meier cumulative percentage curve comparing Ticagrelor 90 mg twice daily versus placebo over 34 days from randomization. The solid line represents Ticagrelor with higher cumulative events, while the dashed line represents placebo with lower cumulative events. A risk table below shows the number of subjects at risk over time for each group.*
FDA Label Image

Figure_5 (Figure 5)

Figure_5 (Figure 5)
A line graph comparing the percentage of IPA induced by 20 uM ADP over time (hours) for three treatments: Ticagrelor 180 mg, Clopidogrel 600 mg, and placebo. The graph shows Ticagrelor reaching close to 90% IPA by 2 hours and maintaining it through 8 hours, Clopidogrel reaching about 50%, and placebo below 10% throughout the time course.*
FDA Label Image

Figure_6 (Figure 6)

Figure_6 (Figure 6)
A line graph comparing IPA (%) induced by 20uM ADP over time (days) among Ticagrelor, Clopidogrel, and Placebo groups. The graph shows Ticagrelor and Clopidogrel with higher IPA percentages than Placebo, decreasing over days up to 10 days. An inset graph displays IPA (%) over hours (0 to 48) with similar groupings and trends.*
FDA Label Image

Figure_7 (Figure 7)

Figure_7 (Figure 7)
A chart titled "Mean effect and 90% CI" comparing pharmacokinetic effects of Ticagrelor and a test compound AR-C124910XX across intrinsic factors such as age, gender, ethnicity, renal impairment, end-stage renal disease on hemodialysis, and mild hepatic impairment. The chart shows mean changes relative to reference values and includes recommendations of "No dose adjustment" for each factor. Pharmacokinetic parameters Cmax and AUC are indicated by squares and triangles, respectively.*
FDA Label Image

Figure_9 (Image 09)

Figure_9 (Image 09)
A chart showing the mean effect and 90% confidence interval of various interacting drugs when combined with Ticagrelor (BRILINTA). It displays change relative to the interacting drug alone for Cmax and AUC values across drugs like Simvastatin, Atorvastatin, and Digoxin, with corresponding dosage recommendations.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.